Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
FDY
Company Profile
Business description
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd is engaged in the research, development, manufacturing, and sale of biopharmaceutical products. Its product portfolio includes ALA (Aminolevulinic acid Hydrochloride); FuMeiDa and Libord. The company has launched it's four types of photodynamic drugs in China market, namely hematoporphyrin, aminolevulinic acid hydrochloride, Verteporfin and Hemoporfin. Geographically, it derives revenue from Mainland China.
Contact
308 Cailun Road
Zhangjiang Hi-Tech Park
Pudong
Shanghai201210
CHNT: +86 2158953355
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
876
Stocks News & Analysis
stocks
Avoid these overvalued ASX shares
The two shares with the highest price to fair value in our Australian coverage.
stocks
Going into earnings, is Microsoft stock a buy, a sell, or fairly valued?
Watching AI monetization, capex’s impact on margins, and guidance on Azure.
stocks
Lithium’s latest drop and what it means for ASX investors
Volatility returns to the lithium market.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,004.90 | 14.70 | 0.16% |
| CAC 40 | 8,436.37 | 73.23 | 0.88% |
| DAX 40 | 25,087.05 | 75.70 | 0.30% |
| Dow JONES (US) | 52,224.64 | 385.38 | 0.74% |
| FTSE 100 | 10,718.20 | 132.29 | 1.25% |
| HKSE | 24,892.66 | 239.63 | -0.95% |
| NASDAQ | 25,837.21 | 329.13 | 1.29% |
| Nikkei 225 | 66,115.60 | 116.59 | -0.18% |
| NZX 50 Index | 13,763.18 | 107.15 | 0.78% |
| S&P 500 | 7,509.20 | 65.92 | 0.89% |
| S&P/ASX 200 | 8,823.00 | 16.50 | 0.19% |
| SSE Composite Index | 3,867.03 | 2.67 | 0.07% |